Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Trevi Therapeutics Inc (TRVI)
NASDAQ:TRVI
Trevi Therapeutics (TRVI) Stock Price & Analysis
280 Followers
TRVI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.97 - $4.00
Previous Close$3.47
Volume117.19K
Average Volume (3M)279.60K
Market Cap
$239.29M
Enterprise Value$157.66M
Total Cash (Recent Filing)$82.97M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)-11.8
Beta1.34
Next Earnings
May 09, 2024EPS Estimate
-$0.09Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding68,960,167
10 Day Avg. Volume320,994
30 Day Avg. Volume279,598
Standard Deviation0.46
R-Squared0.00991
Alpha0.03
Financial Highlights & Ratios
Price to Book (P/B)2.83
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-9.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-6.75
Forecast
1Y Price Target
$7.40Price Target Upside114.49% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TRVI FAQ
What was Trevi Therapeutics Inc’s price range in the past 12 months?
Trevi Therapeutics Inc lowest stock price was $0.97 and its highest was $4.00 in the past 12 months.
What is Trevi Therapeutics Inc’s market cap?
Currently, no data Available
When is Trevi Therapeutics Inc’s upcoming earnings report date?
Trevi Therapeutics Inc’s upcoming earnings report date is May 09, 2024 which is in 21 days.
How were Trevi Therapeutics Inc’s earnings last quarter?
Trevi Therapeutics Inc released its earnings results on Mar 20, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.092 by $0.012.
Is Trevi Therapeutics Inc overvalued?
According to Wall Street analysts Trevi Therapeutics Inc’s price is currently Undervalued.
Does Trevi Therapeutics Inc pay dividends?
Trevi Therapeutics Inc does not currently pay dividends.
What is Trevi Therapeutics Inc’s EPS estimate?
Trevi Therapeutics Inc’s EPS estimate is -$0.09.
How many shares outstanding does Trevi Therapeutics Inc have?
Trevi Therapeutics Inc has 68,960,170 shares outstanding.
What happened to Trevi Therapeutics Inc’s price movement after its last earnings report?
Trevi Therapeutics Inc reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.092. Following the earnings report the stock price went up 4.52%.
Which hedge fund is a major shareholder of Trevi Therapeutics Inc?
Among the largest hedge funds holding Trevi Therapeutics Inc’s share is Viking Global Investors LP. It holds Trevi Therapeutics Inc’s shares valued at 6M.
---
Trevi Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.40 (114.49% Upside)
$7.40 (114.49% Upside)
Hedge Fund Trend
Decreased
By 5.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
91.66%
12-Months-Change
Fundamentals
Return on Equity
-30.59%
Trailing 12-Months
Asset Growth
-27.32%
Trailing 12-Months
Company Description
Trevi Therapeutics Inc
Trevi Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of treatment for neurologically mediated conditions. It focuses on the formulation of nalbuphine ER, which use to treat chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good on March 17, 2011 and is headquartered in New Haven, CT.
---
TRVI Earnings Call
Q4 2024
0:00 / 0:00
---
TRVI Stock 12 Months Forecast
Average Price Target
$7.40
▲(114.49% Upside)
Technical Analysis
Best Analysts Covering TRVI
1 Year
1 Year Success Rate
11/27 ratings generated profit
1 Year Average Return
+14.33%
reiterated a buy rating 28 days ago
Copying Serge Belanger's trades and holding each position for 1 Year would result in 40.74% of your transactions generating a profit, with an average return of +14.33% per trade.
---